Congenital mesoblastic nephroma (CMN) is the most common type of renal tumor in children younger than one year old. Prenatal diagnosis of this benign neoplasm can be achieved using sonography. New developments in sonographic technology, including color and power Doppler, and three-dimensional sonography have improved the detection and diagnosis of CMN in utero. Antenatal diagnosis will allow for optimal postpartum care of the baby. Furthermore, with experience, physicians and sonographers will be able to create a set of guidelines used to discriminate renal masses in utero. This report discusses several useful clinical tools when considering the prenatal diagnosis of congenital mesoblastic nephroma.
Congenital mesoblastic nephroma (CMN) is the most common solid renal tumor found in fetuses and neonates. It can be detected using sonography and magnetic resonance imaging (MRI). This unilateral tumor has a wide spectrum of sonographic characteristics. It can appear either hyperechoic or isoechoic in comparison to the renal parenchyma and is usually heterogeneous in echotexture. Due to its varying appearance, it is difficult to sonographically distinguish this neoplasm from Wilms tumor. Wilms tumor is the most common type of renal malignancy in children. Other pathologies to be considered include angiomyolipoma, focal renal hypertrophy, renal cell carcinoma, nephroblastomatosis (a precursor to Wilms), and nephrogenic adenofibroma.
A review of the current literature on CMN will aid physicians and sonographers because its analysis will provide a set of guidelines for discriminating renal masses in utero. We discuss the pathogenesis of congenital mesoblastic nephroma
Demographics
Congenital mesoblastic nephroma accounts for 75% of all tumors identified in the first six months of life. It is the most common renal neoplasm seen in young infants. It can be identified in children, adolescents, and, rarely, in the adult. CMN is also known as leiomatous hamartoma, fetal renal hamartoma, mesenchymal hamartoma, Bolande's tumor, and congenital fibrosarcoma. 1, 2 The mass usually occurs unilaterally and has a male to female ratio of 1:1. 3 There is no evidence of ethnic influ-ence on the occurrence of CMN, nor is there any hereditary-linked evidence.
CMN is most often identified late in the third trimester of pregnancy. The earliest reported diagnosis of this neoplasm was in the 26th week of gestation. Consideration of gestational age is important when assessing for possible CMN.
Lymphoma, leukemia, and neuroblastoma have been associated with CMN. There is also an increased risk of this neoplasm in patients with Beckwith-Wiedemann syndrome as well as in fetuses with chromosomal abnormalities.
Sonographic Characteristics
CMN typically presents as a solid mass with cystic areas of necrosis in the center. Figures 1 through 3 show a heterogeneous renal mass arising from the kidney. It is often isoechoic in comparison to the renal parenchyma; however, this lesion can appear hypoechoic or hyperechoic relative to the cortex and can arise from any area of the kidney. This lesion is not encapsulated, but it tends to be well circumscribed. Figures 4 and 5 illustrate the classic sonographic characteristics of CMN. With the use of color or power Doppler, a vascular "ring" will illuminate the borders of the mass. It may also demonstrate arteriovenous shunting. 2 MRI may be used prenatally and postnatally to delineate the borders of the mass and provide clear, accurate measurements of the mass. As with any lesion, the presence of enlarged or inflamed lymph nodes in the surrounding area may be suggestive of malignancy. When any mass is detected, scanning the adjacent area for abnormalities is crucial.
Prenatally, this lesion can be fatal if the mass compresses the lungs, resulting in pulmonary hypoplasia. Polyhydramnios is common due to increased urine production from renal hyperfusion as well as decreased gastrointestinal uptake of amniotic fluid due to bowel compression. 4 Hydrops has also been documented with CMN as a result of high cardiac output failure.
Postnatally, patients with CMN most commonly present with a unilateral palpable abdominal mass with distortion of renal parenchyma and/or adjacent anatomy, such as the adrenal gland, liver, bowel, spleen, or diaphragm. Hypercalcemia, hypertension, and elevated plasma total renin concentration (PTRC) are commonly seen in neonates.
These laboratory values have both been reported to return back to normal levels once treatment has begun and the neoplasm is removed. 5 The most significant primary differential diagnosis, Wilms tumor, is nearly indistinguishable from CMN with sonography. Wilms tumors are the most common renal tumor in children one year or older, and there have been very few reported cases of Wilms tumor diagnosed perinatally. 6,7 CMN is therefore more likely to be diagnosed in children younger than a year old.
Treatment
Curative treatment usually consists of postnatal complete or partial nephrectomy of the affected kidney. Although it is a benign lesion, CMN can involve the renal parenchyma, perinephric tissue, or adjacent adrenal gland. Therefore, careful examination to determine the extent of the mass is necessary. Prognosis after nephrectomy is excellent, and chemotherapy is generally not warranted. 3 Although extremely rare, recurrence two years after nephrectomy has been reported.
Review of Literature
Although most of the literature about CMN is consistent with what classic textbooks report, there are several areas that remain unclear and where many authors contradict each other. Many of the dated texts also reference CMN as "congenital Wilms tumor," which is now understood to be incorrect.
Nyberg et al. 1 point out that "polyhydramnios frequently occurs in association with mesoblastic nephroma. . . . A predominantly solid fetal renal mass in the presence of polyhydramnios provides convincing evidence for a mesoblastic nephroma." They also suggest that the neoplasm does not have a well-defined capsule, a topic that other authors contradict. Nyberg et al. argue that focal renal dysplasia should be considered as the primary differential diagnosis to congenital mesoblastic nephroma because it can occur in fetuses or neonates, whereas Wilms tends to occur in children older than one year of age.
Rumack et al. 8 focus on the age of the patient as a marker for CMN. She states, "The young age of the patient, the tumor's benign biologic behavior . . . help to differentiate it from the classic Wilms Tumor." Hagen-Ansert 9 and Callen 6 also use the age of onset as a key marker to differentiate CMN from Wilms tumor. Rumack et al. emphasize the possibility of "local invasion" by the nephroma and that it is important to evaluate the ipsilateral renal vein, inferior vena cava, and right atrium when CMN is suspected. This is contrary to the opinion of Siegel, 7 who suggests that CMN "can invade the perinephric connective tissue, but typically does not infiltrate the vascular pedicle or extend into the renal pelvis."
Goldstein et al. 10 propose the idea that CMN usually arises from the hilus of the kidney and almost always involves the renal sinus. They advocate that watching the mass and the kidney move together during fetal breathing movements affirms that the mass originates from the kidney.
The average size of the CMN is 5 cm in diameter, and it is composed mostly of "stellate and spindleshaped cells that [compress] and infiltrat[e] renal tissue." 5 Wilms tumor, on the other hand, is broken down into two categories. The first is favorable histology, which generally responds better to treatment. Second is unfavorable histology, which is described as "anaplasia, or immature looking cells with deformed or larger than normal nuclei."
Atypical mesoblastic nephroma (AMN) is characterized as a more aggressive form of the neoplasm. It can be distinguished from CMN by its (1) invasion into adjacent structures, such as adrenal gland, spleen, colon, and diaphragm; (2) recurrence; and (3) metastasis. AMN, with its "high cellularity and mitotic index," is very different from CMN and "should be considered as separate from CMN." 5 Kelner et al. 2 focus on the use of different functions of sonography to help distinguish CMN from nephroblastoma, which they emphasize as the principal differential for CMN. They discuss two cases of CMN diagnosed prenatally in which a hypoechoic halo was discovered around the neoplasm. With the use of color and pulsed Doppler, venous and arterial waveforms were detected in the ring. According to Kelner et al., this "hypoechoic ring pattern is commonly seen with CMN." If a complete hypoechoic ring is seen surrounding a thyroid nodule, for example, the nodule is thought to be benign. However, the ring is typically incomplete or not visualized in malignant nodules. 2 This has never been seen in nephroblastoma or atypical mesoblastic nephroma. Figure 6 shows a complete hypoechoic ring surrounding a renal mass. Table 1 shows the radiological and pathological features of tumors with halos surrounding them. use of 3-D sonography to discover the origin of the mass and ensure that it is renal in origin.
CMN has five stages, which are listed in Table  2 . These five stages, like Wilms tumor, coincide with those used for malignant masses; however, there are no reported cases of stage 4 or 5 occurring in typical mesoblastic nephroma. 2 Won et al. 11 advocate using MRI to investigate renal masses, stating that it can be helpful in cases in which sonographic imaging is impaired, such as "maternal obesity, abdominal scars, or oligohydramnios." Tissue contrast also helps to delineate organs and masses as well as provide multiple "imaging planes regardless of fetal position."
Conclusion
Prenatally, new sonographic techniques allow the differentiation of benign and malignant lesions more easily. Benign masses show a hypoechoic halo using 2-D sonography completely surrounding the mass. Color Doppler can be used to highlight the vascular ring surrounding CMN. When this is seen around a mass with low vascularity or the absence of flow inside it, the lesion is suggestive of being benign, although this cannot be certain without a biopsy.
It is crucial to ascertain whether polyhydramnios is present and that the contralateral kidney is not affected.
Three-and four-dimensional sonography can be used to demonstrate the origin of the neoplasm, to confirm its renal nativity. MRI can be used as a complement to sonography when maternal body habitus, amniotic fluid volume, or fetal position may obscure clear, quality sonographic images.
Understanding the classic guidelines for CMN, such as a painless unilateral abdominal mass, hypercalcemia, and hypertension, is essential to arriving at the diagnosis. The key markers to consider when differentiating congenital mesoblastic nephroma from Wilms tumor neonatally are the patients' age, whether or not the mass is encapsulated, and the nature of its infiltration to the renal parenchyma. It is important to examine the perinephric tissue and adrenal gland for local invasion of the lesion and to see if there are any signs of malignancy, such as enlarged lymph nodes, that would suggest a diagnosis of Wilms rather than CMN.
Technology improves the quality of patient care. Having the ability to detect fetal renal masses, such as congenital mesoblastic nephroma, in pregnancy will allow physicians an opportunity to plan for postnatal treatment. It also allows parents to prepare for a child who will need more than standard postnatal care. Early detection of CMN using sonography may result in improved care management and survival. Presence of metastasis (brain, lungs, liver) Stage 5
Presence of bilateral tumors
